Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Assessing Electronic Cigarette Nicotine Flux

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04378907
Recruitment Status : Recruiting
First Posted : May 7, 2020
Last Update Posted : February 11, 2021
Sponsor:
Information provided by (Responsible Party):
Virginia Commonwealth University

Brief Summary:
The purpose of this study is to determine differences in nicotine delivery, use behavior, carbon monoxide delivery, subjective effects, and physiological effects, when cigarette smokers use an electronic cigarette with constant device settings and different e-liquid concentrations.

Condition or disease Intervention/treatment Phase
Electronic Cigarette Use Other: ECIG Lab Session, 30 watts Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 32 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description: The purpose of this study is to determine differences in nicotine delivery, use behavior, (puff topography), and carbon monoxide delivery, subjective effects, and physiological effects, when cigarette smokers use an electronic cigarette with constant device settings and different e-liquid concentrations.
Masking: Single (Participant)
Masking Description: Participants will be blinded to the power level and nicotine concentration used in each session.
Primary Purpose: Basic Science
Official Title: Assessing Electronic Cigarette Nicotine Flux
Actual Study Start Date : January 5, 2021
Estimated Primary Completion Date : April 2022
Estimated Study Completion Date : April 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: E-Cigarettes

Arm Intervention/treatment
Active Comparator: Cigarette Smokers: 0 mg/ml nicotine concentration

ECIG Lab Session, 30 watts, 0 mg/ml nicotine concentration

During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.

Other: ECIG Lab Session, 30 watts
During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.

Experimental: Cigarette Smokers: 4 mg/ml nicotine concentration

ECIG Lab Session, 30 watts, 6 mg/ml nicotine concentration

During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.

Other: ECIG Lab Session, 30 watts
During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.

Experimental: Cigarette Smokers: 15 mg/ml nicotine concentration

ECIG Lab Session, 30 watts, 15 mg/ml nicotine concentration

During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.

Other: ECIG Lab Session, 30 watts
During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.

Experimental: Cigarette Smokers: 30 mg/ml nicotine concentration

ECIG Lab Session, 30 watts, 30 mg/ml nicotine concentration

During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.

Other: ECIG Lab Session, 30 watts
During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.




Primary Outcome Measures :
  1. Plasma Nicotine Concentration [ Time Frame: Approximately 205 minutes ]
    Change in plasma nicotine concentration Blood will be taken 5 times in each session to examine changes from baseline (approx. 90 minutes) to immediately follow a ten-puff bout (approx. 100, 120, and 190 minutes), and immediately after the cigarette challenge paradigm (approx. 205 minutes).

  2. Cigarette Challenge Paradigm [ Time Frame: This task will occur at approximiately 200 minutes until 205 minutes ]
    The cigarette challenge paradigm is a procedure in which participants will be given a 5 minute time period in which they are allowed to smoke their own brand cigarette as much or as little as they want. Study staff will provide the participant with their own brand cigarettes, a lighter, and an ash tray. Latency to start the first puff and number of puffs will be recorded.


Secondary Outcome Measures :
  1. Puff volume [ Time Frame: Puff volume will be measured during the approximately 5-minute, 10-puff use bout. ]
    The volume of each puff, in ml.

  2. Puff duration [ Time Frame: Puff duration will be measured during the approximately 5-minute, 10-puff use bout. ]
    The duration of each puff, measured in second.


Other Outcome Measures:
  1. Change in heart rate [ Time Frame: Baseline to 255 minutes ]
    Change in heart rate, measured in beats per minute.

  2. Inter puff interval [ Time Frame: Inter puff interval will be measured during the approximately 5-minute, 10-puff use bout. ]
    The time between each puff, in seconds.

  3. Flow rate [ Time Frame: Flow rate will be measured during the approximately 5-minute, 10-puff use bout. ]
    The rate of air flow during each puff, in ml/second.

  4. Direct Effects of Vaping Questionnaire [ Time Frame: This measure will be administered at approximately 90, 100, 120, 190, and 205 minutes. ]
    This measure is related to the effects of vaping (10 questions, each scored from 0 - 100).

  5. Direct Effects of Nicotine Questionnaire [ Time Frame: This measure will be administered at approximately 90, 100, 120, 190, and 205 minutes. ]
    This measure is related to the side effects of nicotine (10 questions, each scored from 0 - 100).

  6. Hughes-Hatsukami Questionnaire [ Time Frame: This measure will be administered at approximately 90, 100, 120, 190, and 205 minutes. ]
    This measure is related to nicotine abstinence symptoms (11 questions, each scored from 0 - 100).

  7. General Labeled Magnitude Scale [ Time Frame: This measure will be administered at approximately 90, 100, 120, 190, and 205 minutes. ]
    This measure is related to perceptions of electronic cigarette effects (3 questions, each scored from 0 - 100).

  8. Labeled Hedonic Scale [ Time Frame: This measure will be administered at approximately 90, 100, 120, 190, and 205 minutes. ]
    This measure is related to perceptions of electronic cigarette effects (4 questions, each scored from 0 - 100).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • healthy (determined by self-report)
  • between the ages of 18-55
  • willing to provide informed consent
  • able to attend the lab and abstain from tobacco/nicotine as required and must agree to use designated products according to study protocol

Exclusion Criteria:

• Women if they are breast-feeding or test positive for pregnancy (by urinalysis) at screening.

Some study details about the eligibility criteria are purposely omitted at this time to preserve scientific integrity. Full details will be posted at the conclusion of the study.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04378907


Contacts
Layout table for location contacts
Contact: Alison Breland, PhD (804) 628-2300 abbrelan@vcu.edu
Contact: Thomas Eissenberg, PhD 804-827-3562 teissenb@vcu.edu

Locations
Layout table for location information
United States, Virginia
Center for the Study of Tobacco Products Recruiting
Richmond, Virginia, United States, 23298
Sponsors and Collaborators
Virginia Commonwealth University
Investigators
Layout table for investigator information
Study Director: Alison Breland, PhD Virginia Commonwealth University
Layout table for additonal information
Responsible Party: Virginia Commonwealth University
ClinicalTrials.gov Identifier: NCT04378907    
Other Study ID Numbers: HM20018580
First Posted: May 7, 2020    Key Record Dates
Last Update Posted: February 11, 2021
Last Verified: February 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No